Suspended last week to review reports of unusual blood clots.
According to Reuters, Johnson & Johnson’s Covid-19 vaccine was suspended last week to review reports of unusual blood clots, reporting sales of the drug at $100 million in the first quarter and adjusting its profit forecast for this year.
The company has previously stated that the vaccine will be provided free of charge until the end of the pandemic.
Johnson & Johnson currently expects its full-year adjusted profit to be between US$9.42 and US$9.57 per share, compared with previous estimates of US$9.40-9.60. Previously, sales of its anti-cancer drugs helped its quarterly earnings increase by nearly 7%.
Net income in the first quarter increased from 5.8 billion US dollars or 2.17 US dollars per share in the same period last year to 6.2 billion US dollars or 2.32 US dollars per share.
US regulators suspended the use of the company’s Covid-19 vaccine last week because they reviewed reports of abnormal but severe blood clots in some recipients.